吡咯替尼联合化疗对乳腺癌术后患者的疗效及血清NSE水平的影响

Effect of Pyrrotinib combined with Chemotherapy on the Therapeutic Effect and Serum NSE Level of Postoperative Patients with Breast Cancer

目的 探讨吡咯替尼联合化疗对乳腺癌术后患者的疗效及血清神经元特异性烯醇化酶(NSE)水平的影响。方法 选取2018年8月至2021年12月于龙口市人民医院完成手术治疗的89例乳腺癌患者作为研究对象,根据随机电脑分配原则分为对照组(44例)与吡咯替尼组(45例)。对照组给予紫杉类和蒽环类药物化疗,吡咯替尼组在对照组基础上采用吡咯替尼治疗,比较两组的治疗效果。结果 吡咯替尼组与对照组的客观缓解率分别为88.89%和56.82%,吡咯替尼组的客观缓解率高于对照组(P<0.05)。吡咯替尼组与对照组治疗期间不良反应发生率比较差异无统计学意义(P>0.05)。治疗后,两组血清NSE水平低于治疗前,且吡咯替尼组血清NSE水平低于对照组,差异有统计学意义(P<0.05)。吡咯替尼组无进展生存时间、总生存时间长于对照组(P<0.05)。结论 吡咯替尼联合化疗在乳腺癌术后患者的应用能提高客观缓解率,不会增加不良反应发生率,还可降低血清NSE水平,延长无进展生存时间与总生存时间。

Objective To explore the effect of pyrrotinib combined with chemotherapy on the efficacy and serum neuron-specific enolase(NSE)level in patients with breast cancer after surgery.Methods A total of 89 patients with breast cancer who completed surgical treatment in Longkou People's Hospital from August 2018 to December 2021 were selected as the study objects,and were divided into control group(44 cases)and pyrrotinib group(45 cases)according to random computer allocation principle.The control group was given chemotherapy with taxine and anthracycline,and the pyrrotinib group was treated with pyrrotinib on the basis of the control group.The therapeutic effects of the two groups were compared.Results The objective response rates of the pyrrotinib group and the control group were 88.89%and 56.82%,respectively,and the objective response rates of the pyrrotinib group were higher than those of the control group(P<0.05).There was no significant difference in adverse reactions between the pyrrotinib group and the control group(P>0.05).After treatment,the serum NSE level in the two groups was lower than before treatment,and the serum NSE level in the pyrrotinib group was lower than that in the control group,with statistical significance(P<0.05).The progression-free survival time and overall survival time of pyrrotinib group were longer than those of control group(P<0.05).Conclusion The application of pyrrotinib combined with chemotherapy in postoperative patients with breast cancer can improve the objective response rate without increasing the incidence of adverse reactions,reduce the serum NSE level,and prolong the progression-free survival time and overall survival time.